DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Trump Says Anthropic No Longer Seen as National Security Threat 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
NEW ORLEANS, Jan. 29, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2016 to file lead plaintiff applications in a securities class action lawsuit against Esperion Therapeutics, Inc. (Nasdaq:ESPR), if they purchased the Company’s securities between August 18, 2015 through September 28, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Michigan.
What You May Do
If you purchased shares of Esperion and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 14, 2016.
About the Lawsuit
Esperion and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false statements and omissions include, in part, that: (i) there was no clear path to approval for ETC-1002, a once-daily small molecule designed to lower LDL-cholesterol levels while avoiding the side effects associated with other LDL-cholesterol lowering therapies on the market; (ii) the FDA had encouraged Esperion Therapeutics to initiate a cardiovascular outcomes trial (“CVOT”); and (iii) completion of a CVOT could be necessary prior to approval of ETC-1002.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
